BioMarin Licenses GC Biopharma and Hanmi Pharm’s HM15421/GC1134A for Fabry Disease in a ~$475M Deal

Shots: BioMarin has entered into an exclusive worldwide (ex-Korea) license agreement with GC Biopharma & Hanmi Pharm to develop & commercialize HM15421/GC1134A, an investigational long-acting SC enzyme replacement therapy for Fabry disease GC & Hanmi will receive $70M upfront and are jointly eligible for up to $405M in development & commercial milestones, plus tiered royalties on net sales; GC & Hanmi retain commercialization rights in Korea HM15421/GC1134A, a human recombinant α-Gal A enzyme therapy, is being evaluated in a P-I/II trial; following the study, BioMarin will lead all further development, manufacturing & commercialization; it received the US FDA’s ODD in 2024 Ref: PR Newswire  |   Image: BioMarin  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post BioMarin Licenses GC Biopharma and Hanmi Pharm’s HM15421/GC1134A for Fabry Disease in a ~$475M Deal appeared first on PharmaShots.